Results 41 to 50 of about 26,368 (251)
Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer. Clinical results and biological observations in taxane-pretreated patients [PDF]
, 2015 Background: There is a deep need to improve the care of metastatic breast cancer (MBC) patients, since even today it remains an incurable disease. Taxanes are considered the most effective cytotoxic drugs for the treatment of MBC, both in monotherapy and
Caterino, M. +11 more
core +2 more sources
Verbessert nab-Paclitaxel die Melanom-Chemotherapie? [PDF]
Im Focus Onkologie, 2016 Trotz den Fortschritten in der Immuntherapie spielt die Chemotherapie beim metastasierten Melanom nach wie vor eine wichtige Rolle. Dies zeigt sich in einer aktuellen Phase-III-Studie, in der an Albumin-Nanopartikel gebundenes Paclitaxel (nab-Paclitaxel) mit Dacarbazin verglichen wurde.
Barbara Kreutzkamp, Carola Berking
openaire +1 more source
Thoracic Cancer, 2020 Background Previous trials have suggested that elderly patients with non‐small‐cell lung cancer (NSCLC) could benefit from nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel). Real‐world data on the elderly Chinese population are lacking.
Shuhang Wang +12 more
doaj +1 more source
Frontiers in Public Health, 2021 Purpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC).
Xiaoyan Liu +4 more
doaj +1 more source
Pankreaskarzinom: Langzeitdaten zu nab-Paclitaxel [PDF]
Im Focus Onkologie, 2015 Nab-Paclitaxel konnte in einer grosen Phase-III-Studie das Gesamtuberleben von Patienten mit metastasiertem Pankreaskarzinom verlangern. Nun liegen Langzeitdaten dieser Studie vor.
openaire +1 more source
Therapeutic Advances in Medical Oncology, 2020 Background: The effectiveness of atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer (TNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on advanced TNBC from the US payer perspective. Methods: A Markov model
Bin Wu, Fei Ma
doaj +1 more source
Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use [PDF]
Farmacia Hospitalaria, 2015 Objective: To evaluate the results obtained with the combined use of nab-paclitaxel and gemcitabine in the treatment of patients with metastatic pancreatic adenocarcinoma. Materials and methods: Retrospective observational study.
Elena Ferris Villanueva +5 more
doaj +1 more source
Translational Oncology, 2018 Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is
Md Sazzad Hassan +6 more
doaj +1 more source
Afatinib use in recurrent epithelial ovarian carcinoma. [PDF]
, 2019 •Genomic tumor testing is an important tool in guiding treatment for gynecologic malignancies.•Targetable mutations may lead to new therapies in gynecologic cancer treatment.•Her2/neu mutations in serous ovarian carcinomas can be targeted with ERBB2 ...
Alvarez, Edwin A +3 more
core +1 more source
Dermatology Practical & Conceptual, 2015 Background: Taxanes [paclitaxel, nab-paclitaxel (Abraxane, Celgene Corp, USA), and docetaxel]—used in the treatment of lung, breast, and head and neck cancers—have been associated with cutaneous adverse effects, including photodermatoses.
Bryce D. Beutler, Philip R. Cohen
doaj +1 more source